The ideal model in atherosclerosis and dyslipidaemia - does it exist?
Decisions on the transition from preclinical drug discovery to development are heavily dependent on the data obtained from relevant animal models. Yet, on many occasions, results from animal studies do not translate into human studies. In this editorial, I suggest that in drug discovery the idea of an animal model of a specific disease (in this case dyslipidaemia and atherosclerosis) can lead to unrealistic expectations and that a more mechanistic 'bottom-up' approach is required.